Searchable abstracts of presentations at key conferences in endocrinology

ea0031p62 | Clinical practice/governance and case reports | SFEBES2013

Management of intercurrent illness in adrenal insufficiency

McLatchie Rachel , Strachan Mark W.J. , Gibb Fraser W.

Several recent publications have advocated that patients with primary and secondary adrenal insufficiency (PAI and SAI) be given emergency injectable hydrocortisone to reduce the risk of adrenal crisis. There is a limited evidence-base for this recommendation and consequently the Edinburgh Centre for Endocrinology (ECE) does not routinely issue kits to its patients. This study assessed the frequency of hospital presentations in ECE’s AI patients, and the severity of their...

ea0028p41 | Clinical practice/governance and case reports | SFEBES2012

Low prevalence of pituitary pathology in men presenting with isolated hypogonadotrophic hypogonadism

Gibb Fraser , Strachan Mark , Zammitt Nicola , Walker Brian

Background: Male hypogonadotrophic hypogonadism is an increasingly common cause of referral to endocrine clinics. Subnormal testosterone levels are frequently observed in obesity, type 2 diabetes mellitus and in the elderly. Endocrine Society guidelines suggest stratification of investigations based on the degree of androgen deficiency, with full pituitary function testing and MRI recommended only in those with serum testosterone levels less than 5.2 nmol/L. However the eviden...

ea0027p47 | (1) | BSPED2011

Audit of paediatric patients with IDDM on CSII (pump) therapy in a District General Hospital

Tharian Kavitha , Phillips Geraldine , Fraser Carol , Pryce Rebekah

Introduction: Continuous subcutaneous insulin infusion (CSII) or ‘pump’, therapy is used for intensification of insulin therapy. NICE guideline 2008 recommends CSII as an option for adults / children 12 years or older with insulin dependent diabetes mellitus (IDDM), when multiple daily injection (MDI) insulin therapy results in disabling hypoglycaemia/fails to reduce HbA1c levels below 8.5%, and for children below 12 years whenever MDI is impractical or inappropriate...

ea0025oc2.3 | Steroids | SFEBES2011

APEX1, a novel, negative regulator of aldosterone synthase activity, differentially binds to a single nucleotide polymorphism in the aldosterone synthase gene and represses transcriptional activity both in vitro and in vivo

McManus Frances , Sands William , Fraser Robert , Davies Eleanor , Connell John

Aldosterone synthesis is heritable; a single nucleotide polymorphism (SNP) in the promoter of the aldosterone synthase gene (position −344, rs1799998) has been associated with an increased plasma aldosterone levels and hypertension. However, deletion of this site has no effect on gene transcription in vitro and therefore the mechanism that links genotype with phenotype is unclear.We identified a polymorphism at position −1651 T/C (rs13...

ea0025p275 | Reproduction | SFEBES2011

Male germ cell activity during perinatal reproductive development in the mouse

Jarvis Sheba , Winston Robert , Fraser Scott , Readhead Carol

Dynamic changes in gene expression patterns and cell behaviour are evident throughout embryonic and neonatal germ cell development in the mouse. In the testes, the postnatal period represents a time when the male germline stem cells (GSCs) or, gonocytes migrate to the basement membrane of the seminiferous tubules preparing for a lifetime of spermatogenesis and is an important area of study. Here we use the transgenic mouse that expresses green fluorescent protein under the Oct...

ea0019p9 | Bone | SFEBES2009

Effects of adiponectin on the osteosarcoma cell line Saos-2

Pacheco-Pantoja EL , Sodi R , Gallagher J , Fraser WD

Adiponectin, the most abundant peptide hormone secreted from adipose tissue, has been negatively correlated with obesity and can induce varying responses on bone. There are significant discrepancies in the published data, showing increased, decreased or no effects on bone turnover.We investigated the effects of adiponectin on the human osteosarcoma cell line Saos-2. After culture with varying concentrations of adiponectin (10–100 nM), supernatants w...

ea0015p132 | Diabetes, metabolism and cardiovascular | SFEBES2008

In obese men, lower circulating androgens restrain generation of oestrogens by aromatase, with adverse metabolic effects

Gibb Fraser , Reynolds Rebecca , Phillips David , Andrew Ruth

Objective: Aromatase deficiency in mice or men prevents conversion of androgens to oestrogens and results in central obesity and insulin resistance. In idiopathic obesity, higher aromatase mRNA levels in adipose tissue predict peripheral rather than central fat distribution, but any contribution of aromatase to metabolic complications is unknown. Here, we measured plasma steroids in a large cohort of men and post-menopausal women, in whom aromatase is the major source of oestr...

ea0013p11 | Bone | SFEBES2007

Alendronate accelerates increases in bone mineral density with growth hormone replacement but may attenuate the anabolic effect of growth gormone replacement on bone in adult growth hormone deficiency

White Helen , Ahmad Aftab , Durham Brian , Fraser William , Vora Jiten

Introduction: Adult Growth Hormone Deficiency (AGHD) is associated with osteoporosis. Underlying mechanisms involved in the pathogenesis include reduced target-organ sensitivity to the effect of PTH. Growth Hormone Replacement (GHR) in AGHD leads to increased PTH target-organ sensitivity and consequently increased bone turnover and bone mineral density (BMD).Aims: We determined the effect of alendronate, given in addition to GHR, on PTH target-organ sens...

ea0011p11 | Bone | ECE2006

PTH and phosphate circadian rhythms are altered in adult growth hormone deficient patients with low bone mineral density

White HD , Ahmad AM , Durham BH , Fraser WD , Vora JP

Adult Growth Hormone Deficiency (AGHD) is associated with osteoporosis. PTH is secreted in a circadian rhythm and temporal fluctuations in PTH concentration, particularly at night, appear to be important in the regulation of bone turnover. Serum phosphate is an important determinant of PTH, with changes in phosphate preceding fluctuations in PTH concentration. We examined the difference in PTH and phosphate circadian rhythmicity in AGHD patients with normal and reduced bone mi...

ea0011p12 | Bone | ECE2006

Oral phosphate therapy used as an adjunct to growth hormone in adult growth hormone deficiency results in greater changes in bone mineral density compared with growth hormone replacement alone

White HD , Ahmad AM , Durham BH , Fraser WD , Vora JP

Adult Growth Hormone Deficiency (AGHD) is associated with reduced bone mineral density (BMD) and bone turnover. Abnormalities in PTH circadian rhythmicity, including blunted nocturnal rise in PTH concentration have been reported in AGHD and may underlie the pathogenesis of osteoporosis. Serum phosphate is an important regulator of PTH, with changes in phosphate concentration preceding fluctuations in PTH. We examined the effect of oral phosphate therapy on PTH circadian rhythm...